GlassScriptPhysician profile
Lee S Kosstrin
NPI 1447632740
$6,326.66
in general payments reported to CMS, 2019-2025
40 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $290 · 2021: $750 · 2022: $1,072 · 2023: $941 · 2024: $1,222 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $819.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $769.95 | 2019-2025 | |
| Lilly USA, LLC | $696.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $416.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $348.80 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $258.65 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.42 | 2019-2025 | Jardiance |
| Abbott Laboratories | $243.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $233.52 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $209.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $101.74 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Daiichi Sankyo INC. | $76.48 | 2022-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $76.20 | 2022 | |
| Eisai INC. | $74.83 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Kosstrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.